GlobeNewswire

China Unicom Teams with Cisco to Enable Cloud + Network Synergy with Segment Routing

Dela

BEIJING, April 17, 2018 (GLOBE NEWSWIRE) -- Recently, China United Network Communications Group Co., Ltd. (China Unicom) officially announced seven new products: Cloud Network Connection, Cloud Networking, Cloud VPV, Cloud Broadband, Unicom Cloud Shield, Intelligent Boutique Video Network, and Boutique Financial Network. China Unicom has achieved a major milestone in pursuing network transformation based on Industrial Internet and has become one of the leading service providers in building "cloud + network" synergy.

Cisco has been collaborating with China Unicom for the past two years, to transform the existing traditional nationwide MPLS VPN network into Industrial Internet with the "cloud + network" synergy based on Segment Routing. This project marks a series of firsts:

  • China's first Segment Routing deployment in a service provider's backbone network;
  • the first case of interconnecting equipment from multiple vendors supporting Segment Routing;  
  • the first case of achieving high availability (HA) with controllers from multiple vendors       

Industrial Internet is a concept derived from Consumer Internet. It refers to the practice of traditional industries leveraging the advantage of big data, cloud computing, smart devices and networks to increase internal efficiency and the ability to provide service for external customers. It is one of the most important ways for traditional industries to realize transformation and upgrade through "Internet+".

China Unicom sharply discovered the tremendous opportunity of Industrial Internet and worked on it as a corporate strategy to build China's first on-demand network that provides network routes with minimal latency for customers, supporting minute-level service launch. However, China Unicom's nationwide MPLS VPN backbone network covers 300 cities with more than 1200 devices, and once it is connected with the IP RAN/SPDC metro network in the future, there will be tens of thousands of devices involved. In addition, "cloud + network" integration requires the ability to provide traffic engineering service for each tenant and each application. This presents an unprecedented challenge to network scalability. None of these issues can be solved by traditional RSVP-TE.               

Segment Routing inherent benefits of network simplification, massive scalability and cross-domain operations support perfectly fit with China Unicom's needs. Interoperability between vendors' devices and controllers was a mandatory requirement.

Cisco used the ASR 9000 router series as the Provider Edge router (PE router), and went beyond traditional third-party equipment (using the static Segment Routing solution) to realize the connection of SRTE. As part of the overall solution, Cisco provided its Network Services Orchestrator (NSO) and WAN Automation Engine (WAE), participated in activities such as business modeling, equipment configuration, topology information collection and route calculation for Cisco and third-party equipment, and successfully delivered a multi-vendor Segment Routing solution.

Cisco also worked with China Unicom to drive and achieve high availability (HA) with multiple vendors' SDN controllers. The system can monitor the condition of the master controller. When the master controller fails, the backup controller from a different vendor can smoothly take over all the business models, business examples, as well as configuration and route information, so as to complete the switching. This innovation is of utmost importance for upcoming 5G/large-scale SDN deployment.

Cisco's Advanced Services teams played a major role in the implementation phase of the project. To align with China Unicom's business strategy, Cisco did some "joint development" and customized development through a "three-step" strategy - consulting, implementation, and optimization. Cisco's solution support team acted as the single Point of Contact (PoC) coordinating with related suppliers to follow up and screen problems, and the time needed to solve problems was reduced by 43%.

Ma Jichun, chief engineer from the digital department of China Unicom's design institute CITC, said: "In the context of the new era, China Unicom strives to work with its partners to build a 'cloud + network' ecosystem by actively adopting SDN, NFV, cloud computing, Ultra-broadband Network and other technologies. There is a broad space for China Unicom and Cisco to engage in close collaboration and work together to develop leading technologies such as Segment Routing and SDN. China Unicom will build future networks with an open attitude, to better meet the new needs of customers."

Jonathan Davidson, Senior Vice President and General Manager of Service Provider Networking at Cisco said: "Cisco and China Unicom have worked to transform its networking model and rebuild an intent-based next-generation network. Our collaboration is Cisco's first Segment Routing deployment case in China involving technology from multiple vendors. We look forward to continuing our joint innovative practices, working together to drive the strategic layout and coordinated development of Industrial Internet."  
    
Cisco is leading the disruption in the industry with its technology innovations in systems; silicon; software and security; and its unrivalled expertise in mass-scale networking, automation, optical, optics, cable access, video, and mobility. Combining these capabilities with Cisco's portfolio of go-to-market security, collaboration, IoT, and professional services, we enable service providers, media and web companies to reduce cost and complexity, help secure their networks, and grow revenue.

Supporting Resources

About China Unicom
China Unicom has branch organizations in 31 Chinese provinces (autonomous regions and municipalities) as well as multiple countries and regions outside of China. It is China's only telecom service provider listed on New York City, Hong Kong and Shanghai at the same time. China Unicom ranked No.241 on the 2017 Fortune Global500 list.

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at thenetwork.cisco.com and follow us on Twitter at @Cisco.

RSS Feed for Cisco: http://newsroom.cisco.com/rss-feeds

Sara Cicero
Sr. Public Relations Manager 
Cisco 
Service Provider Business
770-236-2181 direct
770-331-0269 cell 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum